Home > Boards > US Listed > Biotechs > Argenx SE (ARGX)

1-4 Dec 2018: Efgartigimod full Phase II ITP

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
riche Member Profile
 
Followed By 1
Posts 29
Boards Moderated 0
Alias Born 12/15/10
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 1:44:41 PM
argenx announces closing of global offering GlobeNewswire Inc. - 11/12/2019 4:00:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/8/2019 5:19:46 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/8/2019 5:15:58 PM
argenx announces full exercise of underwriters’ option to purchase additional ADSs GlobeNewswire Inc. - 11/8/2019 1:00:00 AM
argenx raises $484 million in gross proceeds in a global offering GlobeNewswire Inc. - 11/6/2019 10:45:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/6/2019 5:28:06 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/6/2019 9:25:37 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/24/2019 7:18:59 AM
argenx reports third quarter 2019 financial results and provides business update GlobeNewswire Inc. - 10/24/2019 1:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/15/2019 4:37:15 PM
argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire Inc. - 9/3/2019 1:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 8/12/2019 2:14:21 PM
argenx to Present at 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire Inc. - 8/6/2019 1:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/1/2019 6:19:00 AM
argenx reports half year 2019 financial results and second quarter business update GlobeNewswire Inc. - 8/1/2019 1:00:00 AM
argenx to report half year 2019 financial results and second quarter business update on August 1, 2019 GlobeNewswire Inc. - 7/25/2019 1:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/28/2019 6:10:44 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/22/2019 6:11:23 AM
argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day GlobeNewswire Inc. - 5/22/2019 1:00:00 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 5/9/2019 5:11:37 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/9/2019 6:52:46 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/8/2019 4:07:37 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 4/10/2019 10:36:38 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 3/26/2019 4:42:53 PM
riche   Tuesday, 10/02/18 04:02:22 AM
Re: riche post# 5
Post # of 10 
1-4 Dec 2018: Efgartigimod full Phase II ITP data, ARGX-110 full Phase I AML dose-escalation data, ARGX-110 full Phase II CTCL data YE 2018: launch of Phase III MG trial with Efgartigimod.



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist